Gatifloxacin

What is Gatifloxacin?[edit | edit source]

Gatifloxacin (ZYMAXID) ophthalmic solution is a topical fluoroquinolone anti-infective used for the treatment of bacterial conjunctivitis.

Gatifloxacin

Gatifloxacin ball-and-stick

Gatifloxacin ZYMAXID is used for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:

Gatifloxacin is a fluoroquinolone antibacterial.
Gatifloxacin is an 8-methoxyfluoroquinolone with a 3-methylpiperazinyl substituent at C7.
The antibacterial action of gatifloxacin results from inhibition of DNA gyrase and topoisomerase IV.
DNA gyrase is an essential enzyme that is involved in the replication, transcription, and repair of bacterial DNA.
Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division.
The mechanism of action of fluoroquinolones including gatifloxacin is different from that of aminoglycoside, macrolide, and tetracycline antibiotics.

Specific drug interaction studies have not been conducted with ZYMAXID® ophthalmic solution.

Initial U.S. Approval: 1999

Recommended dosage: Patients 1 year of age or older:

Instill one drop every two hours in the affected eye(s) while awake, up to 8 times on Day 1.
Instill one drop two to four times daily in the affected eye(s) while awake on Days 2 through 7.

Administration:

Instill one drop two to four times daily in the affected eye(s) while awake.
Patients should be instructed to avoid contaminating the applicator tip with material from the eye, fingers, or other source.
Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis.

This medicine is available in fallowing doasage form:

This medicine is available in fallowing brand namesː ZYMAXID

The most common side effects of this medicine include:

ZYMAXID® solution should not be introduced directly into the anterior chamber of the eye.
As with other anti-infectives, prolonged use of ZYMAXID (gatifloxacin ophthalmic solution) 0.5% may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy.
Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis or during the course of therapy with ZYMAXID.

In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.

Overdose related information is also available online at poisonhelp.org/help.
In the event that the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services. In the United States, call 911.

Because there are no adequate and well-controlled studies in pregnant women, ZYMAXID® solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

The safety and effectiveness of ZYMAXID® in infants below one year of age have not been established.

Active Ingredient:

Inactive Ingredients: edetate disodium water sodium chloride benzalkonium chloride hydrochloric acid sodium hydroxide

Manufactured by: Allergan, Inc. Irvine, CA 92612, U.S.A. ® marks owned by Allergan, Inc. Licensed from Kyorin Pharmaceuticals

Additional barcode labeling by: Physicians Total Care, Inc. Tulsa, Oklahoma

Gatifloxacin Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.